| Endometrial Carcinoma

Jemperli vs Lenvima

Side-by-side clinical, coverage, and cost comparison for endometrial carcinoma.

Deep comparison between: Jemperli vs Lenvima with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsLenvima has a higher rate of injection site reactions vs Jemperli based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Lenvima but not Jemperli, including UnitedHealthcare

Category

Jemperli

Lenvima

At A Glance

RouteIV infusion

FrequencyEvery 3-6 weeks

ClassPD-1 inhibitor

RouteOral

FrequencyOnce daily

ClassMulti-kinase inhibitor

Indications

Endometrial Carcinoma
Solid Neoplasm

Differentiated Thyroid Gland Carcinoma
Renal Cell Carcinoma
Liver carcinoma
Endometrial Carcinoma

Dosing

Endometrial Carcinoma 500 mg IV every 3 weeks for 6 cycles with carboplatin and paclitaxel, followed by 1,000 mg IV monotherapy every 6 weeks; administer prior to carboplatin and paclitaxel when given on the same day.

Endometrial Carcinoma, Solid Neoplasm 500 mg IV every 3 weeks for 4 cycles followed by 1,000 mg IV every 6 weeks as monotherapy; for dMMR-selected patients only.

Differentiated Thyroid Gland Carcinoma 24 mg orally once daily until disease progression or unacceptable toxicity.

Renal Cell Carcinoma (first-line, with pembrolizumab) 20 mg orally once daily in combination with pembrolizumab 200 mg IV infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity or up to 2 years.

Renal Cell Carcinoma (previously treated, with everolimus) 18 mg orally once daily in combination with everolimus 5 mg orally once daily until disease progression or unacceptable toxicity.

Liver carcinoma 12 mg orally once daily for patients >=60 kg or 8 mg orally once daily for patients <60 kg, until disease progression or unacceptable toxicity.

Endometrial Carcinoma 20 mg orally once daily in combination with pembrolizumab 200 mg IV infusion over 30 minutes every 3 weeks until unacceptable toxicity or disease progression.

Contraindications

—

Drug Interactions

189View drug interactions

1071View drug interactions

Adverse Reactions

Most common (>=20%) Fatigue, nausea, diarrhea, constipation, vomiting, anemia, peripheral neuropathy, alopecia, rash, arthralgia, abdominal pain, dyspnea, decreased appetite, urinary tract infection

Serious Sepsis (including urosepsis), pulmonary embolism, urinary tract infection, acute kidney injury, abdominal pain

Most common (>=20%) Hypertension, fatigue, diarrhea, arthralgia/myalgia, decreased appetite, decreased weight, nausea, stomatitis, headache, vomiting, proteinuria, palmar-plantar erythrodysesthesia syndrome, abdominal pain, dysphonia, hypothyroidism, hemorrhagic events, rash, musculoskeletal pain.

Serious Hepatic encephalopathy, hepatic failure, cardio-respiratory arrest, sepsis, myocardial infarction, pneumonitis, acute kidney injury, renal failure, dehydration, thrombocytopenia, dyspnea, anemia.

Postmarketing Pancreatitis, impaired wound healing, cholecystitis, nephrotic syndrome, arterial aneurysms/dissections/rupture.

Pharmacology

Dostarlimab-gxly is a humanized IgG4 monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.

Lenvatinib is a multi-kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 kinase activities as well as FGFR1-4, PDGFRA, KIT, and RET, suppressing pathogenic angiogenesis and tumor growth; in combination with pembrolizumab or everolimus, it demonstrates enhanced antiangiogenic and antitumor activity.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Jemperli